| http://purl.uniprot.org/citations/19843851 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/19843851 | http://www.w3.org/2000/01/rdf-schema#comment | "The transmembrane serine protease hepsin is one of the most highly upregulated genes in prostate cancer. Here, we investigated its tumor-promoting activity by use of a mouse orthotopic prostate cancer model. First, we compared the tumor growth of low hepsin-expressing LnCaP-17 cells with hepsin-overexpressing LnCaP-34 cells. After implantation of cells into the left anterior prostate lobe, LnCaP-34 tumors not only grew faster based on increased serum prostate-specific antigen levels but also metastasized to local lymph nodes and, most remarkably, invaded the contralateral side of the prostate at a rate of 100% compared with only 18% for LnCaP-17 tumors. The increased tumor growth was not due to nonspecific gene expression changes and was not predicted from the unaltered in vitro growth and invasion of LnCaP-34 cells. A likely explanation is that the in vivo effects of hepsin were mediated by specific hepsin substrates present in the tumor stroma. In a second study, mice bearing LnCaP-34 tumors were treated with a PEGylated form of Kunitz domain-1, a potent hepsin active site inhibitor derived from hepatocyte growth factor activator inhibitor-1 (K(i)(app) 0.30 +/-0.02 nmol/L). Treatment of established tumors with PEGylated Kunitz domain-1 decreased contralateral prostate invasion (46% weight reduction) and lymph node metastasis (50% inhibition). Moreover, serum prostate-specific antigen level remained reduced during the entire treatment period, reaching a maximal reduction of 76% after 5 weeks of dosing. The findings show that hepsin promotes invasive prostate tumor growth and metastasis and suggest that active site-directed hepsin inhibition could be effective in prostate cancer therapy."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.org/dc/terms/identifier | "doi:10.1158/0008-5472.can-09-1995"xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Li W."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Moran P."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Ganesan R."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Koeppen H."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Corpuz R."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Gao W.Q."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Kirchhofer D."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Bunting S."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Gogineni A."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Ludlam M.J."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Lipari T."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/author | "Wang B.E."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/date | "2009"xsd:gYear |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/name | "Cancer Res"xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/pages | "8395-8402"xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/title | "Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis."xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://purl.uniprot.org/core/volume | "69"xsd:string |
| http://purl.uniprot.org/citations/19843851 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/19843851 |
| http://purl.uniprot.org/citations/19843851 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/19843851 |
| http://purl.uniprot.org/uniprot/P05981#attribution-7DD1F74FDA173C285BEDC58EE69E3801 | http://purl.uniprot.org/core/source | http://purl.uniprot.org/citations/19843851 |